Earnings manipulation is prevalent throughout the ranks of publicly-traded companies. CFOs have admitted to manipulating earnings and the ongoing Valeant Pharmaceuticals scandal continues to expose the creative ways companies can artificially boost results.
Earnings manipulation is prevalent throughout the ranks of publicly-traded companies. CFOs have admitted to manipulating earnings and the ongoing Valeant Pharmaceuticals scandal continues to expose the creative ways companies can artificially boost results.
Share this Article
Recommended